Pharmacodynamic Evaluation of Rezafungin (CD101) Against Candida auris in the Neutropenic Mouse Invasive Candidiasis Model [Experimental Therapeutics]

Rezafungin (CD101) is a novel echinocandin under development for once-weekly intravenous (IV) dosing. We evaluated the pharmacodynamics (PD) of rezafungin against four Candida auris strains using the neutropenic mouse invasive candidiasis model. AUC/MIC was a robust predictor of efficacy (R² 0.76). The stasis free-drug 24-h AUC/MIC target exposure for the group was 1.88; whereas the 1-log kill free-drug 24-h AUC/MIC target exposure was 5.77. These values are very similar to previous rezafungin PD studies with other Candida spp. Based on recent surveillance susceptibility data, AUC/MIC targets are likely to be exceeded for >90% of C. auris isolates using the previously studied human dose of 400 mg IV once weekly.

https://ift.tt/2Crt282